Your browser is no longer supported. Please, upgrade your browser.
Settings
NKTX [NASD]
Nkarta, Inc.
Index- P/E- EPS (ttm)-2.75 Insider Own0.90% Shs Outstand32.83M Perf Week-3.64%
Market Cap959.98M Forward P/E- EPS next Y-3.22 Insider Trans-18.25% Shs Float29.32M Perf Month-7.69%
Income-72.50M PEG- EPS next Q-0.66 Inst Own80.00% Short Float4.82% Perf Quarter2.52%
Sales- P/S- EPS this Y-684.80% Inst Trans-7.87% Short Ratio4.92 Perf Half Y-13.91%
Book/sh8.78 P/B3.43 EPS next Y-21.10% ROA-21.90% Target Price- Perf Year-3.64%
Cash/sh8.79 P/C3.43 EPS next 5Y- ROE-23.20% 52W Range23.02 - 79.16 Perf YTD-50.95%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-61.91% Beta-
Dividend %- Quick Ratio27.70 Sales past 5Y- Gross Margin- 52W Low30.97% ATR1.74
Employees116 Current Ratio27.70 Sales Q/Q- Oper. Margin- RSI (14)46.91 Volatility4.28% 6.10%
OptionableYes Debt/Eq0.00 EPS Q/Q66.00% Profit Margin- Rel Volume0.62 Prev Close30.74
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume287.43K Price30.15
Recom1.70 SMA20-0.53% SMA50-7.25% SMA200-22.35% Volume179,403 Change-1.92%
Jul-16-21Initiated Oppenheimer Outperform $75
Aug-04-20Initiated Stifel Buy $41
Aug-04-20Initiated Mizuho Buy $34
Aug-04-20Initiated Evercore ISI Outperform $55
Aug-04-20Initiated Cowen Outperform
Sep-14-21 08:32AM  
Aug-12-21 04:02PM  
Jul-14-21 09:07AM  
07:00AM  
Jun-16-21 07:00AM  
Jun-14-21 07:01AM  
Jun-06-21 12:16PM  
May-25-21 07:30AM  
May-13-21 04:02PM  
May-07-21 11:38AM  
May-06-21 04:01PM  
Apr-28-21 08:02AM  
Mar-25-21 04:03PM  
Feb-17-21 04:03PM  
Dec-09-20 03:46PM  
Dec-07-20 03:33PM  
Nov-12-20 04:03PM  
04:02PM  
Nov-09-20 08:02AM  
Nov-05-20 04:02PM  
Oct-12-20 11:03AM  
Oct-05-20 04:02PM  
Sep-29-20 08:02AM  
Sep-08-20 04:02PM  
Aug-20-20 04:02PM  
Jul-31-20 04:42PM  
Jul-14-20 04:39PM  
04:15PM  
Jul-10-20 11:30AM  
08:09AM  
12:44AM  
Nkarta, Inc., a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells. Its two co-lead product candidates are NKX101, which is in Phase I clinical trials for the treatment of relapsed/refractory acute myeloid leukemia or higher risk myelodysplastic syndromes; and NKX019, a pre-clinical product, which is based on the ability to treat various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells. The company was incorporated in 2015 and is based in South San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Brandenberger RalphSee RemarksSep 01Option Exercise3.694,14015,2784,140Sep 02 08:52 PM
Brandenberger RalphSee RemarksSep 01Sale32.084,140132,8110Sep 02 08:52 PM
Rajangam KanyaChief Medical OfficerAug 05Option Exercise0.4110,0004,10010,000Aug 09 05:17 PM
Rajangam KanyaChief Medical OfficerAug 05Sale37.2810,000372,8000Aug 09 05:17 PM
Trager JamesChief Scientific OfficerAug 02Option Exercise3.892,2508,75247,972Aug 04 04:50 PM
Trager JamesChief Scientific OfficerAug 02Sale31.533,600113,50844,372Aug 04 04:50 PM
Mahmood NadirSee RemarksJul 01Option Exercise3.893,50013,61533,788Jul 06 05:11 PM
Mahmood NadirSee RemarksJul 01Sale31.716,500206,11527,288Jul 06 05:11 PM
HASTINGS PAUL JChief Executive OfficerJun 21Sale26.618,500226,218227,561Jun 23 04:05 PM
Mahmood NadirSee RemarksJun 16Option Exercise3.891,8007,00230,288Jun 17 06:06 PM
Brandenberger RalphSee RemarksJun 02Option Exercise3.694,14015,2784,140Jun 04 02:29 PM
Brandenberger RalphSee RemarksJun 02Sale24.504,140101,4300Jun 04 02:29 PM
Mahmood NadirSee RemarksMay 10Sale27.163,00081,48028,488May 12 01:36 PM
Trager JamesChief Scientific OfficerMay 03Option Exercise3.892,2508,75247,972May 05 02:00 PM
Trager JamesChief Scientific OfficerMay 03Sale31.643,600113,90445,722May 05 02:00 PM
Mahmood NadirSee RemarksApr 01Option Exercise3.893,50013,61534,988Apr 02 03:59 PM
Mahmood NadirSee RemarksApr 01Sale32.703,500114,45031,488Apr 02 03:59 PM
HASTINGS PAUL JChief Executive OfficerMar 30Sale30.7417,000522,540236,061Apr 01 06:15 AM
Trager JamesChief Scientific OfficerFeb 02Option Exercise18.002,80050,40049,872Feb 03 07:48 PM
Trager JamesChief Scientific OfficerFeb 02Sale40.002,800112,00047,072Feb 03 07:48 PM
Trager JamesChief Scientific OfficerFeb 01Option Exercise3.892,2508,75250,672Feb 03 07:48 PM
Trager JamesChief Scientific OfficerFeb 01Sale38.673,600139,22947,072Feb 03 07:48 PM
Mahmood NadirSee RemarksJan 25Option Exercise3.895,50021,39536,988Jan 26 04:10 PM
Mahmood NadirSee RemarksJan 25Sale48.575,500267,12031,488Jan 26 04:10 PM
Mahmood NadirSee RemarksJan 14Option Exercise3.893,08311,99331,488Jan 19 10:06 AM
Mahmood NadirSee RemarksDec 03Option Exercise3.893,00011,67028,405Dec 07 08:27 PM